MURATORE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.095
AS - Asia 6.276
EU - Europa 4.326
SA - Sud America 936
AF - Africa 104
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 5
Totale 22.775
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.875
SG - Singapore 2.104
CN - Cina 1.630
IT - Italia 1.020
GB - Regno Unito 944
BR - Brasile 719
HK - Hong Kong 712
VN - Vietnam 638
FI - Finlandia 489
SE - Svezia 391
DE - Germania 386
BD - Bangladesh 337
RU - Federazione Russa 245
FR - Francia 216
KR - Corea 197
UA - Ucraina 147
TR - Turchia 135
NL - Olanda 99
CA - Canada 95
BG - Bulgaria 89
IN - India 86
AR - Argentina 85
ID - Indonesia 85
JP - Giappone 70
AT - Austria 56
MX - Messico 56
IQ - Iraq 54
AE - Emirati Arabi Uniti 36
ES - Italia 34
PL - Polonia 33
AU - Australia 30
EC - Ecuador 30
ZA - Sudafrica 30
IE - Irlanda 29
PK - Pakistan 29
CL - Cile 25
LT - Lituania 23
MA - Marocco 23
VE - Venezuela 22
BZ - Belize 20
CO - Colombia 20
BE - Belgio 18
UZ - Uzbekistan 18
PH - Filippine 16
CH - Svizzera 14
KW - Kuwait 14
PT - Portogallo 14
CZ - Repubblica Ceca 13
MY - Malesia 13
NP - Nepal 13
PE - Perù 13
HU - Ungheria 12
TW - Taiwan 12
GR - Grecia 11
SA - Arabia Saudita 11
DZ - Algeria 10
DO - Repubblica Dominicana 9
KE - Kenya 9
TH - Thailandia 9
AZ - Azerbaigian 8
KG - Kirghizistan 8
PY - Paraguay 8
EG - Egitto 7
UY - Uruguay 7
AL - Albania 6
GT - Guatemala 6
IL - Israele 6
JM - Giamaica 6
JO - Giordania 6
RO - Romania 6
TN - Tunisia 6
CR - Costa Rica 5
EE - Estonia 5
EU - Europa 5
LV - Lettonia 5
PR - Porto Rico 5
IR - Iran 4
SN - Senegal 4
SV - El Salvador 4
BO - Bolivia 3
BY - Bielorussia 3
DK - Danimarca 3
GY - Guiana 3
KH - Cambogia 3
LB - Libano 3
MT - Malta 3
NZ - Nuova Zelanda 3
OM - Oman 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BS - Bahamas 2
CI - Costa d'Avorio 2
CU - Cuba 2
ET - Etiopia 2
KY - Cayman, isole 2
KZ - Kazakistan 2
NI - Nicaragua 2
Totale 22.741
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.546
Singapore 1.266
Ashburn 1.120
Fairfield 1.026
Hong Kong 703
Hefei 586
San Jose 574
Woodbridge 574
Houston 471
Southend 461
Seattle 444
Chandler 438
Helsinki 433
Wilmington 323
Cambridge 305
London 293
Beijing 267
Ann Arbor 255
Nyköping 235
New York 229
Ho Chi Minh City 226
Jacksonville 211
Council Bluffs 207
The Dalles 204
Dearborn 193
Seoul 193
Modena 181
Los Angeles 176
Munich 146
Hanoi 137
Milan 120
Dallas 113
Lauterbourg 113
Chicago 108
San Diego 102
Moscow 98
Buffalo 89
Princeton 78
Sofia 78
São Paulo 71
Shanghai 63
Jakarta 54
Eugene 51
Boardman 46
Bologna 45
Salt Lake City 42
Tokyo 40
Columbus 39
Nuremberg 39
Izmir 37
Redondo Beach 37
Amsterdam 36
Orem 35
Rio de Janeiro 35
Kent 34
Rome 34
Frankfurt am Main 30
Haiphong 30
Redwood City 29
Dublin 27
Toronto 27
Brooklyn 25
Florence 25
Atlanta 24
Da Nang 24
Elk Grove Village 24
Guangzhou 22
Reggio Emilia 22
Mexico City 21
Belize City 20
Vienna 20
Johannesburg 19
Lappeenranta 19
Montreal 19
Brasília 18
Denver 18
Phoenix 18
Brussels 17
Chennai 17
Baghdad 16
Las Vegas 16
Miano 16
Naples 16
Tashkent 16
Warsaw 16
Ankara 15
Kilburn 15
Mumbai 15
Palermo 15
Portsmouth 15
Kuwait City 14
Quito 14
Delft 13
Falls Church 13
Paris 13
Parma 13
Porto Alegre 13
Tampa 13
Norwalk 12
Thái Bình 12
Totale 15.876
Salva come PNG Salva come JPEG
Nome #
Visual loss and other cranial ischaemic complications in giant cell arteritis 347
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 334
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 333
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 310
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 309
Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations 295
Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease 289
L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats 285
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 285
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 280
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 280
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica 277
Biotherapies in large vessel vasculitis 276
Imaging of vasculitis: State of the art 276
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 275
Unmet Needs in the Pathogenesis and Treatment of Vasculitides 273
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 268
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 266
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 265
Biologics in vasculitides: Where do we stand, where do we go from now? 261
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 258
Increased expression of interleukin-22 in patients with giant cell arteritis 254
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 252
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 247
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 246
No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis 241
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 240
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma 235
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab 234
Tocilizumab for the treatment of giant cell arteritis 231
Updates on the diagnosis and monitoring of giant cell arteritis 230
Statin use in giant cell arteritis: a retrospective study 230
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis 230
Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis 228
Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis 228
Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study 227
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 221
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 220
Large-vessel giant cell arteritis: a cohort study 217
Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? 216
Mycophenolate mofetil in primary central nervous system vasculitis 215
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 213
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches 212
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? 212
Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study 212
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 208
miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis 199
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 199
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 197
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 197
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study 195
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study 190
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 189
L30. Assessment of vasculitis extent and severity 187
The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis 187
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 186
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 184
Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years 183
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study 182
Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases 182
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 182
Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis 180
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients 179
Giant Cell Arteritis and Polymyalgia Rheumatica 178
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 175
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study 171
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 169
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 169
Extra-articular rheumatoid arthritis imaged by [18F]FDG-PET/CT 169
Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy 169
Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis 165
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study 162
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 161
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 160
Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica 160
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 160
Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography 158
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 156
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap? 154
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 153
Development of the Takayasu Arteritis Integrated Disease Activity Index 152
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 150
What to Know About Biopsy Sampling and Pathology in Vasculitis? 149
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 148
Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells 148
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 148
Isolated vasculitis of the lower extremities in a patient with polymyalgia rheumatica and giant cell arteritis 146
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 145
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study 143
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 143
Corrigendum to: Increased expression of interleukin-22 in patients with giant cell arteritis 142
Eosinophilic giant cell arteritis: A different subset of disease? 141
Role of miR-146a and miR-146b in Giant Cell Arteritis. 136
Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study 136
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 135
Insight into giant cell arteritis pathogenesis by NanoString nCounter gene expression profiling in temporal artery biopsies 134
Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases 134
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 133
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study 132
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies 132
Totale 20.555
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.494
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.494
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021118 0 0 0 0 0 0 0 0 0 0 0 118
2021/20221.390 77 95 104 83 45 116 131 52 150 114 262 161
2022/20231.409 166 151 111 113 147 183 44 108 206 25 76 79
2023/20241.082 19 70 50 100 190 134 98 172 28 27 63 131
2024/20255.015 138 48 78 342 1.060 826 408 223 534 326 508 524
2025/20269.012 652 414 774 873 960 612 1.203 451 955 684 798 636
Totale 22.995